HIV

Some studies have suggested that patients with HIV have not only a higher risk of lung cancer, but also an increased risk of mortality from lung cancer than patients without HIV.

Velocity of change is key when it comes to falling sodium levels. Hyponatremia is the most common electrolyte disorder seen in hospitals.

Due to lack of data on menopause and HIV, many women living with HIV infection have limited access to medical care and support.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Advancing therapies have resulted in more women living with HIV who experience menopause. Unfortunately, many WLHIV fall into a knowledge gap.

Emergency departments are a safety net for low-income patients, many of whom may be at risk of HIV.

Mylan hopes to launch its newest HIV drug combo at a discounted cost.

Non-disclosure criminal prosecutions among gay, bisexual and other men who have sex with men have been increasing.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Health care providers should be aware of how HIV symptoms may affect menopausal women.

Lower respiratory infections remained the most lethal infectious disease in the United States.

Tenofovir alafenamide plus emtricitabine can be safely used as an alternative to abacavir plus lamivudine in patients with HIV.

A proposed mechanism underlying observed sex differences in HIV-associated vascular risk is increased immune activation in women.

A history of incarceration and homelessness could indicate an increased mortality risk among patients with HIV.

Social and public health providers linking patients to HIV services was found to increase retention in care.

Emergency departments may provide an opportunity to capture those with undiagnosed HIV infection missed by screening programs.

Women with a prior chlamydia infection could have twice the risk of ovarian cancer.

Ibalizumab-uiyk was the first monoclonal antibody approved to treat HIV.

This article highlights several key therapeutics areas with ibalizumab-uiyk that every pharmacist should know.

None of the participants experienced grade 3 or 4 side effects.

A continuing concern is HIV-associated neurologic syndromes.

The median time to viral suppression decreased from 63 days to 45 days post-rapid entry program.

Top news of the day from across the health care landscape.